Resource data sheet
DNA Bank Top
Please review the QC test results indicated by check icon below as well as clone information before placing your order.

pCMV_s-FLAGc (#RDB07396)

Destination vector to generate mammalian expression vector, with FLAG-tag.

Clone info. Destination vector to generate mammalian expression vector, with FLAG-tag. Derived from pCMV_S-FLAG (RDB05956). Gateway compatible.
Vector backbone Plasmid
Size of vector backbone 7.5 kb
Selectable markers Amp^r (E. coli), Neo^r (mammalian cell)
Growth conditions 37C, LB+Amp
Growth remarks Use DB3.1, ccdB Survival or equivalent to amplify this clone. 30 degC is fine.
Depositor|Developer DNA Bank, | Murata, Takehide |
 
Sequence (full) RDB07396zzt02.seq compiled by us
Remarks, protocol and/or map (pdf) RDB07396.pdf

Distribution information

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
Ordering forms
Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ]
MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ]
Please visit Information of Request for Distribution.[link] 
Terms and conditions for distribution The RECIPIENT agrees to describe RIKEN BRC as the source of the MATERIAL in any publication.
Additional terms and conditions:
Regrding pRc/CMV:
a) The modified pRc/CMV, and their descendants (collectively, LIFE MATERIALS), should be used for pre-clinical/non-human, research use only.
b) LIFE MATERIALS shall not be used for any commercial purposes.
c) LIFE MATERIALS shall not be transferred beyond the specified recipient.
d) Recipient must contact Thermo Fisher Scientific Inc. at outlicense@thermofisher.com for any desired use of LIFE MATERIALS beyond the scope of a) to c) above.
Remarks Use DB3.1(Invitrogen) or equivalent to amplify this clone.
Gateway® Expression clone. Please refer Life Technologies Corporation signs license agreement with RIKEN BRC.
提供案内 (日本国内) [open/close]

必要書類
提供依頼書  [依頼書の記入例 ]
提供同意書 (MTA, 非営利学術目的用)[Word] [MTAの記入例 ]
手続きの概要は、「提供申込みについて[link]」をご覧ください。
MTAに書く使用条件 本件リソースは非営利機関にのみ提供し、学術研究にのみ利用することができる。発表に際し、理研BRCから入手したことを明記すること。
付加的使用条件：
pRc/CMVについて:
a) The modified pRc/CMV, and their descendants (collectively, LIFE MATERIALS), should be used for pre-clinical/non-human, research use only.
b) LIFE MATERIALS shall not be used for any commercial purposes.
c) LIFE MATERIALS shall not be transferred beyond the specified recipient.
d) Recipient must contact Thermo Fisher Scientific Inc. at outlicense@thermofisher.com for any desired use of LIFE MATERIALS beyond the scope of a) to c) above.
備考 このクローンの増殖にはDB3.1(Invitrogen)あるいは同等の宿主を使用してください。
Gateway®テクノロジーを用いた発現クローンです。「Gateway®テクノロジーを用いたクローンの提供と寄託のご案内」をご覧ください。

Catalog # Resource name Shipping form Fee
RDB07396 pCMV_s-FLAGc DNA solution

Please review the QC test results indicated by check icon below as well as clone information before placing your order.

How to cite this biological resource

Materials & Methods section:

The pCMV_s-FLAGc was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB07396).

Reference section:

Further references such as user reports and related articles (go to bottom)

QC test results

RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by check icon as well as clone information before placing your order.

Test sheet Data Sheet open check

Nucleotide sequence of a portion of this resource (if available).

Primer: CMV-Forward
Sequence file: RDB12331_A5J8a.seq check
>07396_12331_A5J8_CMV-Forward_A09_03.ab1
    1 ACGAACAACT CCGCCCCATT GACGCAATGG GCGGTAGGCG TGTACGGTGG GAGGTCTATA
   61 TAAGCAGAGC TCTCTGGCTA ACTAGAGAAC CCACTGCTTA CTGGCTTATC GAAATTAATA
  121 CGACTCACTA TAGGGAGACC CAAGCTGAAT TCACCATGGA CTACAAGGAC GATGACGATA
  181 AGGCGGCCAT CACAAGTTTG TACAAAAAAG CTGAACGAGA AACGTAAAAT GATATAAATA
  241 TCAATATATT AAATTAGATT TTGCATAAAA AACAGACTAC ATAATACTGT AAAACACAAC
  301 ATATCCAGTC ACTATGGCGG CCGCATTAGG CACCCCAGGC TTTACACTTT ATGCTTCCGG
  361 CTCGTATAAT GTGTGGATTT TGAGTTAGGA TCCGTCGAGA TTTTCAGGAG CTAAGGAAGC
  421 TAAAATGGAG AAAAAAATCA CTGGATATAC CACCGTTGAT ATATCCCAAT GGCATCGTAA
  481 AGAACATTTT GAGGCATTTC AGTCAGTTGC TCAATGTACC TATAACCAGA CCGTTCAGCT
  541 GGATATTACG GCCTTTTTAA AGACCGTAAA GAAAAATAAG CACAAGTTTT ATCCGGCCTT
  601 TATTCACATT CTTGCCCGCC TGATGAATGC TCATCCGGAA TTCCGTATGG CAATGAAAGA
  661 CGGTGAGCTG GTGATATGGG ATAGTGTTCA CCCTTGTTAC ACCGTTTTCC ATGAGCAAAC
  721 TGAAACGTTT TCATCGCTCT GGAGTGAATA CCACGACGAT TTCCGGCAGT TTCTACACAT
  781 ATATTCGCAA GATGTGGCGT GTTACGGTGA AAACCTGGCC TATTTCCCTA AAGGGTTTAT
  841 TGAGAATATG TTTTTCGTCT CAGCCAATCC CTGGGTGAGT TTCACCAGTT TTGATTTAAA
  901 CGTGGCCAAT ATGGACAACT TCTTTCGCCC CCGTTTTCAC CATGGGCAAA TATTATACGC
  961 AAGGCGACAA GGTGCTGATG CCGCTGGCGA TTCAGGTTCA TCATGCCGGT TTGTGATGGC
 1021 TTCCATGTCG GCAGAATGCT TAAATGAATT TACAACAGTA CTGCGATGAG TGGCAGGCGG
 1081 GCGTAAACGC GTGGAATTCT GCTAACTAAA GTCAAGAATA ACAGGTAATG CGTATTTTGG
1141 CGCGCGCCTT GAATATTTTT GTGGCGGG
//
Primer: BGH_rev
Sequence file: RDB12331_A5J8b.seq check
>07396_12331_A5J8_BGHrev_B09_06.ab1
    1 GTTCTTGCAA TTTAGGTGAC TATAGAATAG GGCCCTCTAG ATGCATGCTC GAGCGGCCAT
   61 CACCACTTTG TACAAGAAAG CTGAACGAGA AACGTAAAAT GATATAAATA TCAATATATT
  121 AAATTAGATT TTGCATAAAA AACAGACTAC ATAATACTGT AAAACACAAC ATATCCAGTC
  181 ACTATGGTCG ACCTGCAGAC TGGCTGTGTA TAAGGGAGCC TGACATTTAT ATTCCCCAGA
  241 ACATCAGGTT AATGGCGTTT TTGATGTCAT TTTCGCGGTG GCTGAGATCA GCCACTTCTT
  301 CCCCGATAAC GGAGACCGGC ACACTGGCCA TATCGGTGGT CATCATGCGC CAGCTTTCAT
  361 CCCCGATATG CACCACCGGG TAAAGTTCAC GGGAGACTTT ATCTGACAGC AGACGTGCAC
  421 TGGCCAGGGG GATCACCATC CGTCGCCCGG GCGTGTCAAT AATATCACTC TGTACATCCA
  481 CAAACAGACG ATAACGGCTC TCTCTTTTAT AGGTGTAAAC CTTAAACTGC ATTTCACCAG
  541 CCCCTGTTCT CGTCAGCAAA AGAGCCGTTC ATTTCAATAA ACCGGGCGAC CTCAGCCATC
  601 CCTTCCTGAT TTTCCGCTTT CCAGCGTTCG GCACGCAGAC GACGGGCTTC ATTCTGCATG
  661 GTTGTGCTTA CCAGACCGGA GATATTGACA TCATATATGC CTTGAGCAAC TGATAGCTGT
  721 CGCTGTCAAC TGTCACTGTA ATACGCTGCT TCATAGCATA CCTCTTTTTG ACATACTTCG
  781 GGTATACATA TCAGTATATA TTCTTATACC GCAAAAATCA GCGCGCAAAT ACGCATACTG
  841 TTATCTGGCT TTTAGTAAGC CGGATCCACG CGTTTACGCC CCGCCCTGCC ACTCATCGCA
  901 GTACTGTTGT AATTCATTAA GCATTCTGCC GACATGGAAG CCATCACAAA CGGCATGATG
  961 AACCTGAATC GCCAGCGGCA TCAGCACCTT GTCGCCTTGC GTATAATATT TGCCCATGGG
 1021 TGAAAACGGG GGGCGAAGAA AGTTGTCCAT ATTGGCCACG TTTTAAATCA AAACTGATGA
 1081 AACTCCACCC AGGGGATTTG ACCTGAGACG GAAAAACAAT ATTTCTCAAT AAACCCCTTT
1141 TAAGGGGAAA TATAGGGCCA G
//
Primer: SV40pro_F_V2
Sequence file: RDB12331_A5J8c.seq check
>07396_12331_A5J8_SV40pro_F_V2_C09_09.ab1
    1 GTACCGGCTT TTTTGGAGGC TAGGCTTTTG CAAAAGCTCC CGGGAGCTTG GATATCCATT
   61 TTCGGATCTG ATCAAGAGAC AGGATGAGGA TCGTTTCGCA TGATTGAACA AGATGGATTG
  121 CACGCAGGTT CTCCGGCCGC TTGGGTGGAG AGGCTATTCG GCTATGACTG GGCACAACAG
  181 ACAATCGGCT GCTCTGATGC CGCCGTGTTC CGGCTGTCAG CGCAGGGGCG CCCGGTTCTT
  241 TTTGTCAAGA CCGACCTGTC CGGTGCCCTG AATGAACTGC AGGACGAGGC AGCGCGGCTA
  301 TCGTGGCTGG CCACGACGGG CGTTCCTTGC GCAGCTGTGC TCGACGTTGT CACTGAAGCG
  361 GGAAGGGACT GGCTGCTATT GGGCGAAGTG CCGGGGCAGG ATCTCCTGTC ATCTCACCTT
  421 GCTCCTGCCG AGAAAGTATC CATCATGGCT GATGCAATGC GGCGGCTGCA TACGCTTGAT
  481 CCGGCTACCT GCCCATTCGA CCACCAAGCG AAACATCGCA TCGAGCGAGC ACGTACTCGG
  541 ATGGAAGCCG GTCTTGTCGA TCAGGATGAT CTGGACGAAG AGCATCAGGG GCTCGCGCCA
  601 GCCGAACTGT TCGCCAGGCT CAAGGCGCGC ATGCCCGACG GCGAGGATCT CGTCGTGACC
  661 CATGGCGATG CCTGCTTGCC GAATATCATG GTGGAAAATG GCCGCTTTTC TGGATTCATC
  721 GACTGTGGCC GGCTGGGTGT GGCGGACCGC TATCAGGACA TAGCGTTGGC TACCCGTGAT
  781 ATTGCTGAAG AGCTTGGCGG CGAATGGGCT GACCGCTTCC TCGTGCTTTA CGGTATCGCC
  841 GCTCCCGATT CGCAGCGCAT CGCCTTCTAT CGCCTTCTTG ACGAGTTCTT CTGAGCGGGA
  901 CTCTGGGGTT CGAAATGACC GACCAAGCGA CGCCCAACCT GCCATCACGA GATTTCGATT
  961 CCACCGCCGC CTTCTATGAA AGGTTGGGCT TCGGAATCGT TTTCCGGGAC GCCCGGCTGG
 1021 ATGATCCCTC CAGCGCGGGG GATCTCATGC TGGAGTTCTC GCCCACCCCA ACATGTTAAT
 1081 GCCAGCTTAT ATGGTTACCA ATAAAGCATA GCATTCCAAC AAATTCCAAC AAAAATAAAG
1141 CCATTTTTTT TTTTCA
//

Please visit Sequencing and PCR primers for primer information.

References

Original, user report and related articles